Results 131 to 140 of about 6,623 (181)

Acellular Pertussis Vaccines for Adolescents

The Pediatric Infectious Disease Journal, 2005
The epidemiology of pertussis is changing, with a clear increase in the number of cases diagnosed in adolescents and adults. This development has spurred studies and anticipated licensure of safer diphtheria, tetanus, acellular pertussis combined (Tdap) vaccines for this older population.Literature review.Tdap vaccines are safe and immunogenic when ...
Michael E, Pichichero, Janet R, Casey
openaire   +2 more sources

Acellular Pertussis Vaccine Booster

Pediatrics, 1993
The editors of Pediatrics have asked us to comment on the study by Pichichero et al,1 because our report of booster vaccination with this vaccine, published in Pediatrics in 1989,2 raised some questions with regard to the safety of the vaccine. The present study, with a design similar to ours, showed different and far more encouraging results: no ...
M, Blennow, M, Granstrom
openaire   +2 more sources

The Efficacy of Acellular Pertussis Vaccine

JAMA: The Journal of the American Medical Association, 1989
To the Editor.— Reporting from a workshop at the National Institutes of Health, Bethesda, Md, 1 Mr Marwick stated that "the large Swedish field trial of two acellular pertussis vaccines 2 has not shown levels of efficacy high enough to make either vaccine a likely candidatefor immediate licensure in the United States." We can now report efficacy data ...
P, Olin, J, Storsaeter, V, Romanus
openaire   +2 more sources

Standardization of Acellular Pertussis Vaccines

Biologicals, 1999
In comparison with the current whole cell pertussis vaccine, the new generation of acellular pertussis vaccines opens new opportunities to improve the standardization of the product, because well defined and characterized components are used in these new products.However, different compositions, purification and inactivation methods are used by ...
openaire   +2 more sources

Acellular Vaccines and Resurgence of Pertussis

JAMA, 2012
PERTUSSIS IS A HIGHLY CONTAGIOUS, VACCINEpreventable disease for which a whole-cell vaccine (killed bacteria), in combination with toxoids against diphtheria and tetanus (DTwP), was introduced for immunization of children in the United States in the 1940s. With the eventual widespread use of DTwP vaccine, the national annual incidence of reported cases
openaire   +2 more sources

Acellular Pertussis Vaccines--A Solution to the Pertussis Problem

Journal of Infectious Diseases, 1993
Available data relating to pertussis and pertussis immunization are frequently overlooked or misinterpreted. Mortality due to pertussis is underreported. Most whole cell pertussis vaccines are effective; there is no evidence that pertussis vaccines cause brain damage.
openaire   +4 more sources

Combination vaccines consisting of acellular pertussis vaccines

The Pediatric Infectious Disease Journal, 1997
Combination vaccines consisting of multiple vaccine antigens delivered in a single injection simplify vaccine administration. Combining multiple antigens into one injection, however, presupposes that the administration of multiple vaccines in combination will not reduce the safety and immunogenicity of the component vaccines.
K M, Edwards, M D, Decker
openaire   +2 more sources

Potency testing of acellular pertussis vaccines

Vaccine, 1992
The laboratory assessment of the potential of acellular pertussis vaccines to protect against human disease is a major problem. The mouse intracerebral challenge test, which is the accepted potency assay for whole cell pertussis vaccines, is not suitable for testing acellular vaccines, and more recently developed murine respiratory infection assays ...
A, Robinson, S G, Funnell
openaire   +2 more sources

The purification and characterization of an acellular pertussis vaccine

Journal of Biological Standardization, 1988
An acellular pertussis vaccine manufactured by Biken was investigated for purity, potency and toxicity. The vaccine was composed of almost equal proportions of pertussis toxin (PT) and filamentous hemagglutinin (FHA). The purity of the vaccine was 97-99%.
M, Chazono, I, Yoshida, T, Konobe, K, Fukai   +3 more
openaire   +2 more sources

Efficacy of an acellular pertussis vaccine in Japan

The Journal of Pediatrics, 1985
To assess the efficacy of an acellular pertussis vaccine that has been used in Japan since 1981, 283 patients with pertussis were selected among patients with suspected pertussis seen at hospitals located around the Tokyo Metropolitan area from 1981 to 1983. The survey of secondary cases in household contacts showed that attack rates in children 0 to 6
T, Aoyama, Y, Murase, T, Kato, T, Iwata
openaire   +2 more sources